Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH – Get Free Report) reached a new 52-week high on Wednesday . The stock traded as high as $37.97 and last traded at $38.61, with a volume of 124897 shares traded. The stock had previously closed at $34.51.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the stock. Citigroup assumed coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 target price for the company. Oppenheimer initiated coverage on shares of Sensei Biotherapeutics in a research report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 price target on the stock. BTIG Research reiterated a “buy” rating and issued a $55.00 price objective on shares of Sensei Biotherapeutics in a research note on Thursday, July 16th. HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Finally, Citizens Jmp assumed coverage on shares of Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $55.00.
Sensei Biotherapeutics Stock Performance
Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.04) by $2.20. Research analysts expect that Sensei Biotherapeutics, Inc. will post -13.18 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Sensei Biotherapeutics news, CFO Brian C. Stephenson bought 9,391 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were purchased at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the transaction, the chief financial officer directly owned 26,804 shares in the company, valued at approximately $700,388.52. The trade was a 53.93% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Anand Kiran Parikh bought 2,806 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of $19.76 per share, with a total value of $55,446.56. Following the purchase, the chief executive officer owned 764,234 shares of the company’s stock, valued at approximately $15,101,263.84. This represents a 0.37% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 49,494 shares of company stock valued at $1,188,822 in the last three months. 7.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Sensei Biotherapeutics
A number of hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 10.6% in the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Sensei Biotherapeutics during the second quarter worth $307,000. Bank of America Corp DE increased its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Sensei Biotherapeutics during the second quarter worth $3,610,000. Finally, Stempoint Capital LP bought a new position in shares of Sensei Biotherapeutics in the 1st quarter valued at $4,188,000. 10.50% of the stock is currently owned by institutional investors and hedge funds.
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Featured Articles
- Five stocks we like better than Sensei Biotherapeutics
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
- Strategic Strike: Strategy Deploys $370M to Fortify Bitcoin
- Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
- From High Dividend Growth to High Yield, These 3 Stocks Just Boosted Dividend Payouts
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
